Amgen to continue to seek full approval of Lumakras cancer drug after FDA panel votes against it

Amgen will continue to seek full approval for its Lumakras cancer drug as a treatment for a form of lung cancer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.